Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials-Reference-Cited by-同舟云学术

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

Published:2022-02 Issue:2 Volume:21 Page:125-139
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Mignot Emmanuel,Mayleben David,Fietze Ingo,Leger Damien,Zammit Gary,Bassetti Claudio L A,Pain Scott,Kinter Dalma Seboek,Roth Thomas

Funder

Idorsia Pharmaceuticals Ltd

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference27 articles.

1. Diagnostic and Statistical Manual of Mental Disorders,2013

2. Insomnia disorder;Morin;Nat Rev Dis Primers,2015

3. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians;Qaseem;Ann Intern Med,2016

4. European guideline for the diagnosis and treatment of insomnia;Riemann;J Sleep Res,2017

5. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update;Wilson;J Psychopharmacol,2019

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study;Sleep Medicine;2024-10

2. Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder;Sleep Medicine;2024-10

3. Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports;Journal of Affective Disorders;2024-10

4. Discovery, synthesis and SAR of 2-acyl-1-biarylmethyl pyrazolidines, dual orexin receptor antagonists designed as fast and short-acting sleeping drugs;Bioorganic & Medicinal Chemistry;2024-10

5. Current and Emerging Sleep Interventions for Older Adults with or without Mild Cognitive Impairment;Current Treatment Options in Neurology;2024-09-04